Table 2.
Current clinical trials in metastatic uveal melanoma.
| Mechanism | Trial | Phase | Identifier | Status |
|---|---|---|---|---|
| Targeted therapy | ||||
| PKC/MEK | AEB071 + BYL719 | I | NCT02273219 | Accrual complete |
| Intermittent selumetinib | I | NCT02768766 | Recruiting | |
| Selumetinib +/– paclitaxel | II | ISRCTN29621851 | Recruiting | |
| Binimetinib + AEB071 * | I/II | NCT01801358 | Terminated | |
| LXS196 | I | NCT02601378 | Recruiting | |
| Multikinase inhibition | Sorafenib (STREAM) | II | NCT01377025 | Accrual complete |
| Cabozantinib versus temozolomide/dacarbazine | II | NCT01835145 | Accrual complete | |
| Immunotherapy | ||||
| Checkpoint blockade | Pembrolizumab | II | NCT02359851 | Accrual complete |
| Ipilimumab + nivolumab | II | NCT01585194 | Recruiting | |
| Ipilimumab + nivolumab | II | NCT02626962 | Accrual complete | |
| Ipilimumab + radioembolization * | I | NCT01730157 | Terminated | |
| Ipilimumab + nivolumab + radioembolization | 0 | NCT02913417 | Recruiting | |
| TILs | Tumor infiltrating lymphocytes | II | NCT01814046 | Accrual complete |
| Cellular adoptive immunotherapy + ipilimumab | I | NCT03068624 | Recruiting | |
| T cell redirection | IMCgp100 (second-line) | I | NCT02570308 | Recruiting |
| IMCgp100 (first-line) | II | NCT03070392 | Recruiting | |
| Antibody–drug conjugate | Glembatumumab vedotin | II | NCT02363283 | Accrual complete |
| Epigenetic therapy | ||||
| HDAC inhibition | Vorinostat | II | NCT01587352 | Accrual on hold |
| Pembrolizumab + entinostat (PEMDAC) | II | NCT02697630 | Recruiting | |
| BET inhibition | PLX51107 | I | NCT02683395 | Recruiting |
| Liver-directed therapy | ||||
| IHP | IHP versus best alternative care (SCANDIUM) | III | NCT01785316 | Recruiting |
| PHP | PHP versus TACE, dacarbazine, ipilimumab, or pembrolizumab (FOCUS) | III | NCT02678572 | Recruiting |
*
Study terminated for scientific or other reasons. BET, bromodomain and extra-terminal; HDAC, histone deacetylase; IHP, isolated hepatic perfusion; PHP, percutaneous hepatic perfusion; TIL, tumor infiltrating lymphocyte.